Furthermore, while complement proteins, urine MCP-1 (uMCP-1), adiponectin, and hepcidin have been proposed as candidate LN flare cycle biomarkers, it is presently not clear how these would be used clinically to provide diagnostic, pathologic, or therapeutic information on each phase of the flare cycle to significantly impact LN treatment. Here, HAMP is linked to lobular neoplasia.